MGMT and glioblastoma: Since the landmark study by Hegi et al.[1] numerous clinical trials in glioblastoma have confirmed that hypermethylation of the MGMT promoter serves as a strong prognostic factor for progression-free survival (PFS) and overall survival (OS) [1], [2], [3], [4], [5], [6].